Treace Medical Concepts, Inc. provided revenue guidance for the year 2024. For the period, the company expects revenue to be $220 million to $225 million, which represents approximately 18% to 20% growth over full-year 2023 revenue.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4.568 USD | +4.28% | -59.28% | -64.20% |
05-08 | Top Midday Decliners | MT |
05-08 | UBS Adjusts Price Target on Treace Medical Concepts to $16 From $17, Maintains Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-64.20% | 272M | |
+73.38% | 12.41B | |
-18.29% | 8.23B | |
-0.13% | 6.46B | |
+15.76% | 5.5B | |
-4.95% | 5.33B | |
+40.80% | 5.1B | |
-18.32% | 4.05B | |
-29.48% | 2.54B | |
+7.56% | 1.99B |
- Stock Market
- Equities
- TMCI Stock
- News Treace Medical Concepts, Inc.
- Treace Medical Concepts, Inc. Provides Revenue Guidance for the Year 2024